GENSCRIPT BIO (01548) rose more than 5%, with the stock up 5.03% to HK$15.23 at the time of writing, with a turnover of HK$296.96 million. The increase follows a surge of over 10% in the share price of its associate company, Legend Biotech, overnight. Legend Biotech yesterday announced its unaudited financial results and key highlights for the first quarter of 2026. Compared to the first quarter of 2025, net sales of CARVYKTI® in Q1 2026 grew by 62% to approximately $597 million. Within this, net sales in the U.S. market increased by 36%, while net sales in markets outside the U.S. surged by 222%. Additionally, the company's net loss for the three months ended March 31, 2026, narrowed to $54.3 million, compared to a net loss of $101.0 million in the same period last year.